Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group maintains an Outperform rating on Akero Therapeutics (NASDAQ:AKRO) but lowers the price target from $50 to $38.
May 15, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evercore ISI Group maintains an Outperform rating on Akero Therapeutics but lowers the price target from $50 to $38.
The Outperform rating suggests a positive outlook, but the lowered price target indicates tempered expectations. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100